Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Renormax: Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Renormax - General Information

Renormax is an ACE inhibitor antihypertensive drug used to treat hypertension. Like many ACE inhibitors, this is a prodrug which is converted to the active metabolite spiraprilat following oral administration. ACE inhibitors are used primarily in treatment of hypertension and congestive heart failure.

 

Pharmacology of Renormax

Renormax is an angiotensin-converting enzyme (ACE) inhibitor. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. By blocking ACE, spirapril decreases angiotensin II which is a vasoconstrictor.

 

Additional information about Renormax

Renormax Indication: Used to treat hypertension. Mechanism Of Action: Renormaxat, the active metabolite of spirapril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Renormaxat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin. Drug Interactions: Not Available Food Interactions: Avoid alcohol.Avoid salt substitutes containing potassium.Avoid natural licorice.Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication. Generic Name: Spirapril Synonyms: Not Available Drug Category: Antihypertensive Agents; Angiotensin-converting Enzyme Inhibitors Drug Type: Small Molecule; Approved Other Brand Names containing Spirapril: Renormax; Absorption: Bioavailability is 50% following oral administration. Toxicity (Overdose): Not Available Protein Binding: Not Available Biotransformation: Hepatic. Converted to spiraprilat following oral administration. Half Life: 30 to 35 hours Dosage Forms of Renormax: Not Available Chemical IUPAC Name: (7S)-8-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1,4-dithia-8-azaspiro[4.4]nonane-7-carboxylic acid Chemical Formula: C22H30N2O5S2 Spirapril on Wikipedia: https://en.wikipedia.org/wiki/Spirapril Organisms Affected: Humans and other mammals